ストックスクリーナーアプリを入手
0.3801
8.50%
-0.0353
アフターアワーズ：
.36
-0.0201
-5.29%
Gossamer Bio Inc (GOSS) 最新ニュース
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension - Finviz
Quarterly Trades: Should I set a stop loss on Gossamer Bio IncJuly 2025 Trends & Technical Pattern Based Signals - baoquankhu1.vn
Barclays downgrades Gossamer Bio (GOSS) - MSN
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Re - GuruFocus
Gossamer Bio stock downgraded by Wedbush on trial results - Investing.com South Africa
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Reduction | GOSS Stock News - GuruFocus
These Analysts Slash Their Forecasts On Gossamer Bio - Benzinga
GOSS: Analyst Downgrades and Price Target Slashes by Leerink Par - GuruFocus
GOSS Sees Significant Downgrade as Barclays Lowers Price Target - GuruFocus
This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Barclays cuts Gossamer Bio stock rating on trial results By Investing.com - Investing.com Australia
Leerink Downgrades Gossamer Bio to Market Perform From Outperform, Adjusts Price Target to $1 From $6 - marketscreener.com
Leerink cuts Gossamer Bio stock rating on trial miss - Investing.com Australia
Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story - TechStock²
Barclays cuts Gossamer Bio stock rating on trial results - Investing.com
Gossamer Bio’s seralutinib misses primary endpoint in PAH trial By Investing.com - Investing.com India
Leerink cuts Gossamer Bio stock rating on trial miss By Investing.com - Investing.com Canada
GOSS: Gossamer Bio's Phase 3 Study of Seralutinib Shows Promise in PAH - GuruFocus
Gossamer Bio stock plummeted 82% today — what’s behind the crash? - MSN
Gossamer Bio’s seralutinib misses primary endpoint in PAH trial - Investing.com Australia
Gossamer Bio’s Phase 3 PROSERA PAH Trial Misses Primary Endpoint Despite Numerical 6MWD Gain - Yahoo Finance
BREAKING: Gossamer Bio Investors Should Contact Block & - GlobeNewswire
Gossamer slides on phase III readout of seralutinib in PAH - bioworld.com
Gossamer Bio (GOSS) Faces Setback in Phase 3 Trial Results - GuruFocus
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study - AOL.com
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Asianet Newsable
Gossamer Bio Shareholders Are Encouraged to Contact Johnson - GlobeNewswire
GOSS Faces Setback with Phase 3 PROSERA Results in Pulmonary Hyp - GuruFocus
Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks - Benzinga
Gossamer Bio Reveals Mixed Phase 3 Seralutinib Results - TipRanks
Gossamer Bio Reports Phase 3 Trial of Seralutinib Missed Primary Endpoint - marketscreener.com
Gossamer Bio stock tumbles 80% on trial miss By Investing.com - Investing.com Canada
Gossamer Bio Inc. (Ticker: GOSS) recently disclosed the topline data from its Phase III clinical trial, the Prosera study. - Bitget
Gossamer Bio reports PROSERA topline: missed primary 6MWD endpoint but secondary endpoints and high-risk subgroup favored seralutinib - TradingView
Gossamer Bio shares plummet as lung disease drug fails late-stage trial - Reuters
Gossamer Bio's experimental lung condition drug fails in late-stage trial - TradingView
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - The Joplin Globe
Monaco Asset Management SAM Sells 2,170,584 Shares of Gossamer Bio, Inc. $GOSS - MarketBeat
How Gossamer Bio Inc. stock reacts to Fed rate cuts2025 Trading Recap & Weekly Stock Breakout Alerts - mfd.ru
Street Watch: What is FATEs P E ratio telling usJuly 2025 Selloffs & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Gossamer Bio (NASDAQ:GOSS): The High-Stakes Gamble Drawing Big Bank Interest - AOL.com
Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS) - MarketBeat
A Big Test For SeralutinibWill Gossamer's PAH Data Win Investors' Hearts This Month? - RTTNews
A Look At Gossamer Bio (GOSS) Valuation After Barclays Strong Buy Upgrade And Rising Institutional Ownership - Yahoo Finance
Gossamer Bio’s Stock Whipsaws As Biotech Investors Weigh Risk, Cash Runway And Pipeline Hopes - AD HOC NEWS
Brokers Offer Predictions for Gossamer Bio FY2030 Earnings - MarketBeat
Big Money Bets On Gossamer Bio (GOSS) As Institutional Ownership Hits 81 Percent - AOL.com
Is Gossamer Bio Inc. forming a breakout patternJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - mfd.ru
MB Generational Wealth LLC Buys Shares of 1,414,824 Gossamer Bio, Inc. $GOSS - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Trading Down 4.7%Here's What Happened - MarketBeat
Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation - Insider Monkey
1.52%
1.68%
大文字化:
|
ボリューム (24 時間):